Q-omics provides the consensus-scored TUBAP4 profile across patient tissues and cancer cell-line models. TUBAP4 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TUBAP4 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TUBAP4 RNA expression shows 8,729 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where TUBAP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBAP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBAP4 survival associations across molecular data types. TUBAP4 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBAP4 RNA expression–survival associations across cancer types. High TUBAP4 expression shows unfavorable associations in MESO, DLBC, COAD, READ and BLCA, but favorable associations in SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TUBAP4 RNA expression.
This table summarizes TUBAP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TUBAP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBAP4 shows lower tumor expression in ESCA and LUSC and higher tumor expression in KIRC, COAD, BRCA and KIRP. The KIRC box plot shows higher TUBAP4 RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .017).
This table shows molecular features associated with TUBAP4 in patient tissues and cancer cell lines. In patient samples, TUBAP4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
